A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

• Status: Active, not recruiting
• Trial end date: 2021-10-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants must have gradual and progressive change in memory function for >6 months.

• Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.

Exclusion Criteria:

• Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study.

• Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy <24 months.

• Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread.

• Participants must not have serious risk for suicide.

• Participants must not have history of drug or alcohol use disorder within the last 2 years.

• Participants must not have multiple severe drug allergies

• Participants must not have HIV, Hepatitis B or Hepatitis C

• Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy